BRAF and neoplasm: If downregulation of BRaf with anti-BRafV600E therapy also causes sodium iodide symporter upregulation, as suggested by in vitro data, it could be expected that patients treated with anti-B-RafV600E therapy may undergo both reduction of tumor size/invasiveness and possible redifferentiation, thus making radioactive iodine administration possible to control an additional metastatic burden [78, 81–83].